TY - JOUR
T1 - Cancer therapy with iron oxide nanoparticles
T2 - Agents of thermal and immune therapies
AU - Soetaert, Frederik
AU - Korangath, Preethi
AU - Serantes, David
AU - Fiering, Steven
AU - Ivkov, Robert
N1 - Funding Information:
R.I., P.K., and F.S. received partial funding from the Jayne Koskinas and Ted Giovanis Foundation for Health and Policy (JKTGF); R.I. and P.K. also received partial funding from the National Cancer Institute (5R01CA194574-02 and 5R01CA247290). D.S acknowledges Xunta de Galicia for financial support under the I2C Plan and the Strategic Grouping in Materials (AeMAT; grant No. ED431E2018/08). The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins University, JKTGF, NIH, other funding agencies.
Funding Information:
R.I. P.K. and F.S. received partial funding from the Jayne Koskinas and Ted Giovanis Foundation for Health and Policy (JKTGF); R.I. and P.K. also received partial funding from the National Cancer Institute (5R01CA194574-02 and 5R01CA247290). D.S acknowledges Xunta de Galicia for financial support under the I2C Plan and the Strategic Grouping in Materials (AeMAT; grant No. ED431E2018/08). The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins University, JKTGF, NIH, other funding agencies.
Publisher Copyright:
© 2020 The Authors
PY - 2020/1
Y1 - 2020/1
N2 - Significant research and preclinical investment in cancer nanomedicine has produced several products, which have improved cancer care. Nevertheless, there exists a perception that cancer nanomedicine ‘has not lived up to its promise’ because the number of approved products and their clinical performance are modest. Many of these analyses do not consider the long clinical history and many clinical products developed from iron oxide nanoparticles. Iron oxide nanoparticles have enjoyed clinical use for about nine decades demonstrating safety, and considerable clinical utility and versatility. FDA-approved applications of iron oxide nanoparticles include cancer diagnosis, cancer hyperthermia therapy, and iron deficiency anemia. For cancer nanomedicine, this wealth of clinical experience is invaluable to provide key lessons and highlight pitfalls in the pursuit of nanotechnology-based cancer therapeutics. We review the clinical experience with systemic liposomal drug delivery and parenteral therapy of iron deficiency anemia (IDA) with iron oxide nanoparticles. We note that the clinical success of injectable iron exploits the inherent interaction between nanoparticles and the (innate) immune system, which designers of liposomal drug delivery seek to avoid. Magnetic fluid hyperthermia, a cancer therapy that harnesses magnetic hysteresis heating is approved for treating humans only with iron oxide nanoparticles. Despite its successful demonstration to enhance overall survival in clinical trials, this nanotechnology-based thermal medicine struggles to establish a clinical presence. We review the physical and biological attributes of this approach, and suggest reasons for barriers to its acceptance. Finally, despite the extensive clinical experience with iron oxide nanoparticles new and exciting research points to surprising immune-modulating potential. Recent data demonstrate the interactions between immune cells and iron oxide nanoparticles can induce anti-tumor immune responses. These present new and exciting opportunities to explore additional applications with this venerable technology. Clinical applications of iron oxide nanoparticles present poignant case studies of the opportunities, complexities, and challenges in cancer nanomedicine. They also illustrate the need for revised paradigms and multidisciplinary approaches to develop and translate nanomedicines into clinical cancer care.
AB - Significant research and preclinical investment in cancer nanomedicine has produced several products, which have improved cancer care. Nevertheless, there exists a perception that cancer nanomedicine ‘has not lived up to its promise’ because the number of approved products and their clinical performance are modest. Many of these analyses do not consider the long clinical history and many clinical products developed from iron oxide nanoparticles. Iron oxide nanoparticles have enjoyed clinical use for about nine decades demonstrating safety, and considerable clinical utility and versatility. FDA-approved applications of iron oxide nanoparticles include cancer diagnosis, cancer hyperthermia therapy, and iron deficiency anemia. For cancer nanomedicine, this wealth of clinical experience is invaluable to provide key lessons and highlight pitfalls in the pursuit of nanotechnology-based cancer therapeutics. We review the clinical experience with systemic liposomal drug delivery and parenteral therapy of iron deficiency anemia (IDA) with iron oxide nanoparticles. We note that the clinical success of injectable iron exploits the inherent interaction between nanoparticles and the (innate) immune system, which designers of liposomal drug delivery seek to avoid. Magnetic fluid hyperthermia, a cancer therapy that harnesses magnetic hysteresis heating is approved for treating humans only with iron oxide nanoparticles. Despite its successful demonstration to enhance overall survival in clinical trials, this nanotechnology-based thermal medicine struggles to establish a clinical presence. We review the physical and biological attributes of this approach, and suggest reasons for barriers to its acceptance. Finally, despite the extensive clinical experience with iron oxide nanoparticles new and exciting research points to surprising immune-modulating potential. Recent data demonstrate the interactions between immune cells and iron oxide nanoparticles can induce anti-tumor immune responses. These present new and exciting opportunities to explore additional applications with this venerable technology. Clinical applications of iron oxide nanoparticles present poignant case studies of the opportunities, complexities, and challenges in cancer nanomedicine. They also illustrate the need for revised paradigms and multidisciplinary approaches to develop and translate nanomedicines into clinical cancer care.
KW - Cancer
KW - Immune therapy
KW - Iron deficiency anemia
KW - Iron oxide nanoparticles
KW - Magnetic nanoparticle hyperthermia
KW - Nanomedicine
UR - http://www.scopus.com/inward/record.url?scp=85087680262&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087680262&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2020.06.025
DO - 10.1016/j.addr.2020.06.025
M3 - Review article
C2 - 32603814
AN - SCOPUS:85087680262
SN - 0169-409X
VL - 163-164
SP - 65
EP - 83
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
ER -